VYVGART sales reach new highs as label expands
- Third-quarter 2026 product net sales reached $1.7 billion, up 54% year over year.
- United States sales accounted for $1.5 billion of the quarterly revenue.
- The company plans to file for approval in immune-mediated necrotizing myopathy by year-end.
- A pivotal trial readout for empasiprubart in multifocal motor neuropathy is expected in December 2026.
- Management halted the UNITY trial in Sjögren's syndrome for futility.
A rare disease winner with momentum
argenx has evolved into a highly profitable drug company. VYVGART continues to exceed expectations, producing $1.7 billion of product net sales in the third quarter of 2026. The recent approval for seronegative generalized myasthenia gravis is creating a positive halo effect, increasing prescribers across all patient types.
The bull case relies on adding patient groups while maintaining pricing power. Management is targeting up to five new launches in 2027 to support their long-term growth plan. Near-term catalysts include the pivotal EMPASSION readout for empasiprubart in December 2026 and a pediatric FDA decision in February 2027.
The bear case centers on clinical execution and pipeline setbacks. While recent data supports a regulatory filing for immune-mediated necrotizing myopathy, the FDA is requiring an additional study for dermatomyositis. Furthermore, the company halted a trial in Sjögren's syndrome due to futility. Investors are closely watching trial outcomes to justify the current valuation.
High-priced drugs for rare diseases
argenx sells biologic medicines for rare autoimmune diseases. These drugs are complex antibody therapies, not simple pills. The main product is efgartigimod, sold as VYVGART for intravenous use and VYVGART Hytrulo for under-the-skin injection.
Most revenue comes from treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Both are serious immune-driven nerve and muscle diseases. Payers often accept high prices because the patient populations are small and the medical need is severe.
The shift to prefilled syringes lets more patients self-administer at home. This format grows volume but shifts U.S. reimbursement from Medicare medical coverage to pharmacy coverage. This shift initially raised gross-to-net discounts earlier in the year. Management notes that these adjustments and U.S. net pricing stabilized in the third quarter, easing concerns about margin pressure.
One engine with several shots
VYVGART and VYVGART Hytrulo in gMG
The core franchise is driving current revenue. The label now covers all adult patients, including those who are triple seronegative.
VYVGART Hytrulo in CIDP
CIDP is a major growth driver. Early launch momentum was strong, and investors are watching to see if growth continues beyond initial switch patients.
Efgartigimod in myositis
Positive ALKIVIA data supports a regulatory filing for IMNM by year-end. However, dermatomyositis will require an additional registrational study.
Empasiprubart
This is a second pipeline antibody in registrational studies. The pivotal multifocal motor neuropathy readout in December 2026 is a major test.
FB102
Acquired from Forte, this asset demonstrated positive Phase II results in celiac disease. It is now advancing into Phase III studies.
ARGX-119
Currently in a registrational study for congenital myasthenic syndrome. It provides argenx another opportunity outside the VYVGART franchise.
United States drives the revenue
This mix uses Q3 2026 product net sales by region: $1.5 billion in the U.S., $158 million in rest of world, $81 million in Japan, and $11 million from product supply to Zai Lab in China. The company is highly concentrated in VYVGART.
What could break the story
CIDP growth slows after early switch patients
High impact · Medium oddsThe early CIDP launch benefited from patients switching from existing therapies. That pool may not last forever. If new patient starts begin to slow down, the market may question the total size of the CIDP opportunity.
Gross-to-net discounts pressure profit margins
Medium impact · Medium oddsSelf-injection shifted more U.S. use into pharmacy benefit channels, which raised gross-to-net discounts earlier in the year. While discounts stabilized in the third quarter, a renewed increase would pressure profits.
Pipeline readouts fail to show superiority
High impact · Medium oddsargenx relies on repeated clinical wins to expand its label. Following the halt of the UNITY trial, attention turns to whether empasiprubart can demonstrate superiority, not just non-inferiority, to existing treatments in upcoming readouts.
Biosimilars arrive after exclusivity ends
High impact · Low oddsVYVGART has a long runway, but not a permanent one. The base regulatory exclusivity period is expected to run until December 2033 in the U.S. and August 2032 in the EU.
In one breath
What does argenx sell?
argenx sells VYVGART and VYVGART Hytrulo, versions of efgartigimod. They are antibody medicines used for rare immune nerve and muscle diseases such as gMG and CIDP.
Why is VYVGART important to ARGX stock?
VYVGART is the main revenue engine. It generated $1.7 billion of product net sales in the third quarter of 2026 and drives the company's profitability.
What changed with the seronegative gMG approval?
The FDA expanded VYVGART and VYVGART Hytrulo to all adult gMG patients in the U.S. That includes triple seronegative patients who previously had no approved treatment option.
What is the biggest risk for argenx now?
The main near-term risk is whether CIDP keeps growing after early switch patients. A second risk is clinical trial failure, as seen with the recent halt of the Sjögren's syndrome trial.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- October 25, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near argenx SE in Finn's Biotechnology industry ranking.

